RxDoctor Payments Data

Ebtisam Alumin Osman, MD

Neurology · Atlanta, GANPI 1659759207

Payments from drug & device makers

$4,484in general payments, 2019–2025

Across 106 payments — averaging $42.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2K
  • Jazz Pharmaceuticals Inc.$591
  • UCB, Inc.$523
  • AbbVie$403
  • Argenx US, Inc.$145
  • Pfizer$125
  • plus $926 from 20 others

What the payments were for

  • Travel & lodging$1,10225%
  • Food & beverage$3,38275%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,484 in reported general payments places this provider in the 60th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$81,290
Medicare patients
439
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)30$269,925
IngrezzaValbenazine Tosylate11$89,103
Nurtec OdtRimegepant Sulfate37$50,965
QuliptaAtogepant24$38,234
Lamictal XrLamotrigine11$37,066
UbrelvyUbrogepant20$26,845
Aimovig AutoinjectorErenumab-Aooe22$21,978
Lacosamide133$15,423
Emgality PenGalcanezumab-Gnlm20$14,929
Depakote ErDivalproex Sodium17$12,272
Levetiracetam181$7,165
Memantine Hcl169$5,205
Felbamate12$3,646
Gabapentin166$3,400
Donepezil Hcl219$2,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$58$89,10311 claims
AbbVieQulipta, Ubrelvy$403$65,07944 claims
PfizerNurtec Odt$125$50,96537 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$16$84213 claims
Upsher-smith Laboratories LLCTopiramate$87$54944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →